FDA grants fast track designation for Kintara's breast cancer therapy

The US FDA has granted fast track designation (FTD) for Kintara Therapeutics’ REM-001, to treat cutaneous metastatic breast cancer (CMBC).

Related Keywords

,Menu Hover ,Subchild Level Menu Hover ,Child Level Menu Hover ,End Third Level ,Bend Article ,End Timeline ,